British Journal of Dermatology, 2020 Tralokinumab is a fully human monoclonal antibody that specifically neutralizes interleukin‐13, a key driver of atopic dermatitis (AD).
J. Silverberg +11 more
semanticscholar +1 more source
Severe Atopic Dermatitis In Spain: A Real-Life Observational Study [PDF]
, 2019 Objective: To determine the epidemiology and characterize the treatment prescribed for severe atopic dermatitis (AD) in children/adults in usual clinical practice.
Armario Hita, José Carlos +2 more
core +2 more sources
Atopic Dermatitis and Comorbidity [PDF]
Healthcare, 2020 Atopic dermatitis is the most common chronic inflammatory skin disease. It is often the first indicator of allergic diseases, and a certain percentage of patients are affected by allergic rhinitis and/or asthma as a consequence. The study aimed to investigate the link between atopic dermatitis and comorbidity in family medicine.
Sanja Bekić +5 more
openaire +3 more sources
Trial of Nemolizumab and Topical Agents for Atopic Dermatitis with Pruritus.
New England Journal of Medicine, 2020 BACKGROUND Nemolizumab is a subcutaneously administered humanized monoclonal antibody against interleukin-31 receptor A, which is involved in pruritus and inflammation in atopic dermatitis.
K. Kabashima +3 more
semanticscholar +1 more source
Atopic Dermatitis Host and Environment Model: Revisiting Therapeutic Options [PDF]
, 2020 Atopic Dermatitis affects both children and adults and is a serious health concern in many countries. AD is a complex disease with host and environmental factors underlying its pathology. Its treatment is multidimensional reflecting the diverse nature of
Abreu, C +3 more
core +1 more source
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis.
New England Journal of Medicine, 2016 BACKGROUND Dupilumab, a human monoclonal antibody against interleukin-4 receptor alpha, inhibits signaling of interleukin-4 and interleukin-13, type 2 cytokines that may be important drivers of atopic or allergic diseases such as atopic dermatitis ...
E. Simpson +24 more
semanticscholar +1 more source
Consensus on the therapeutic management of atopic dermatitis - Brazilian Society of Dermatology [PDF]
Anais Brasileiros de Dermatologia, 2019 : BACKGROUND: Atopic dermatitis is a highly prevalent inflammatory and pruritic dermatosis with a multifactorial etiology, which includes skin barrier defects, immune dysfunction, and microbiome alterations.
Valeria Aoki +17 more
doaj +1 more source
Intelectin contributes to allergen-induced IL-25, IL-33, and TSLP expression and type 2 response in asthma and atopic dermatitis. [PDF]
, 2017 The epithelial and epidermal innate cytokines IL-25, IL-33, and thymic stromal lymphopoietin (TSLP) have pivotal roles in the initiation of allergic inflammation in asthma and atopic dermatitis (AD).
Cheng, D +12 more
core +1 more source
Burden and socioeconomics of asthma, allergic rhinitis, atopic dermatitis and food allergy
Expert review of pharmacoeconomics & outcomes research, 2020 Introduction Asthma, allergic rhinitis, atopic dermatitis, and food allergy affect approximately 20% of the global population. Few studies describe the burden of the totality of these diseases and only a handful studies provide a comprehensive overview ...
B. Dierick +6 more
semanticscholar +1 more source
Inflammatory cytokines and biofilm production sustain Staphylococcus aureus outgrowth and persistence: A pivotal interplay in the pathogenesis of Atopic Dermatitis [PDF]
, 2018 Individuals with Atopic dermatitis (AD) are highly susceptible to Staphylococcus aureus colonization. However, the mechanisms driving this process as well as the impact of S. aureus in AD pathogenesis are still incompletely understood.
A Matlow +88 more
core +1 more source